New Research on Hematological Malignancies

Haematological malignancies are a significant health care challenge, and cytogenetic and molecular markers are essential for identification, treatment, and prognosis. Isocitrate dehydrogenase mutations can be treated with inhibitors, Selinexor, and poly(ADP-ribose) polymerase inhibitors are useful in the treatment of myelodysplastic syndrome and acute myeloid leukaemia.

Format: Paperback / softback
Length: 145 pages
Publication date: 01 October 2021
Publisher: Nova Science Publishers Inc

Haematological malignancies, which encompass cancers that impact the blood, bone marrow, and lymph nodes, pose a significant challenge in healthcare. In Chapter One, we delve into the realm of cytogenetic and molecular markers, highlighting their pivotal role in the identification, treatment, and prognosis of patients with myeloproliferative neoplasms. We explore the significance of these markers in understanding the genetic makeup of these diseases and guiding personalized treatment strategies.

Chapter Two delves into the effectiveness of targeting isocitrate dehydrogenase mutations in myeloid hematologic malignancies through the use of inhibitors of this enzyme. We examine the clinical outcomes and mechanisms of action of these inhibitors in treating patients with these diseases.

Chapter Three explores the use of Selinexor and other drugs in the treatment of hematologic malignancies. We discuss their mechanisms of action, clinical trials, and potential benefits in the management of various types of blood cancers.

Chapter Four delves into the utility of poly(ADP-ribose) polymerase inhibitors in the treatment of myelodysplastic syndrome and acute myeloid leukaemia. We examine the mechanisms of action, clinical trials, and emerging evidence supporting their use as targeted therapies for these diseases.

These chapters provide a comprehensive overview of haematological malignancies, highlighting the importance of cytogenetic and molecular markers, targeted therapies, and novel drug interventions in the management and treatment of these complex diseases. By understanding the underlying biology and clinical implications of these markers and therapies, oncologists can better tailor treatment plans and improve patient outcomes.

Weight: 240g
ISBN-13: 9781536199550